Literature DB >> 2884230

Effect of estrogen on the growth hormone response to the alpha-adrenergic agonist clonidine in women with menopausal flushing.

T Tulandi, S Lal, H Guyda.   

Abstract

The serum GH response to the alpha 2-adrenergic receptor agonist clonidine (0.15 mg, iv) was measured in 8 postmenopausal women with hot flushes before and during treatment with the conjugated estrogen premarin (1.25 mg, orally daily for 4 weeks), 9 normal premenopausal women, and 12 normal men. The men had a significantly greater GH response than did the age-matched premenopausal women (P less than 0.05). The mean individual peak GH response was significantly higher in the premenopausal compared with the postmenopausal women (P less than 0.05). Premarin decreased the number of hot flushes (P less than 0.01), but had no effect on the GH response to clonidine. These results suggest that estrogens do not enhance alpha 2-adrenergic mechanisms that regulate GH secretion and that improvement in menopausal flushing after estrogen therapy is not mediated by an effect on central alpha 2-adrenergic function.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2884230     DOI: 10.1210/jcem-65-1-6

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  2 in total

1.  Effect of sleep deprivation on the growth hormone response to the alpha-3 adrenergic receptor agonist, clonidine, in normal subjects.

Authors:  S Lal; J X Thavundayil; B Krishnan; N P Nair; G Schwartz; M E Kiely; H Guyda
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  Growth hormone response to apomorphine in obsessive-compulsive disorder.

Authors:  W Pitchot; M Hansenne; A G Moreno; M Ansseau
Journal:  J Psychiatry Neurosci       Date:  1996-11       Impact factor: 6.186

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.